Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimo Offidani

Showing results (61-70 of 149) with videos related to

Pageof 15
Sort By:
Clinical Lymphoma & Myeloma|October 16, 2008
Serum C-reactive protein at diagnosis and response to therapy is the most powerful factor predicting outcome of multiple myeloma treated with thalidomide/ anthracycline-based therapyMassimo Offidani, Laura Corvatta, Claudia Polloni, et al.
European Journal of Haematology|July 8, 2005
Long-term experience with low-dose interferon-alpha and PUVA in the management of early mycosis fungoidesSerena Rupoli, Gaia Goteri, Stefano Pulini, et al.
Leukemia & Lymphoma|May 26, 2010
Melphalan, prednisone, and thalidomide versus thalidomide, dexamethasone, and pegylated liposomal doxorubicin regimen in very elderly patients with multiple myeloma: a case-match studyMassimo Offidani, Pietro Leoni, Sara Bringhen, et al.
European Journal of Haematology|March 25, 2010
ThaDD plus high dose therapy and autologous stem cell transplantation does not appear superior to ThaDD plus maintenance in elderly patients with de novo multiple myelomaMassimo Offidani, Pietro Leoni, Laura Corvatta, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 18, 2012
Assessment of vulnerability measures and their effect on survival in a real-life population of multiple myeloma patients registered at Marche Region Multiple Myeloma RegistryMassimo Offidani, Laura Corvatta, Claudia Polloni, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 5, 2014
Very low rate of readmission after an early discharge outpatient model for autografting in multiple myeloma patients: an Italian multicenter retrospective studyMassimo Martino, Mauro Montanari, Felicetto Ferrara, et al.
Critical Reviews in Oncology/Hematology|July 2, 2011
Primary plasma cell leukemia in the era of new drugs: has something changed?Pellegrino Musto, Livio Pagano, Maria Teresa Petrucci, et al.
Leukemia & Lymphoma|February 23, 2011
Infectious complications in patients with multiple myeloma treated with new drug combinations containing thalidomideMassimo Offidani, Laura Corvatta, Claudia Polloni, et al.
Haematologica|May 10, 2007
Pegylated liposomal doxorubicin in the treatment of primary cutaneous T-cell lymphomasStefano Pulini, Serena Rupoli, Gaia Goteri, et al.
American Journal of Hematology|December 23, 2016
Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trialsMassimo Gentile, Valeria Magarotto, Massimo Offidani, et al.
Pageof 15

Showing results (61-70 of 149) with videos related to

Sort By:
Pageof 15
Clinical Lymphoma & Myeloma|October 16, 2008
Serum C-reactive protein at diagnosis and response to therapy is the most powerful factor predicting outcome of multiple myeloma treated with thalidomide/ anthracycline-based therapyMassimo Offidani, Laura Corvatta, Claudia Polloni, et al.
European Journal of Haematology|July 8, 2005
Long-term experience with low-dose interferon-alpha and PUVA in the management of early mycosis fungoidesSerena Rupoli, Gaia Goteri, Stefano Pulini, et al.
Leukemia & Lymphoma|May 26, 2010
Melphalan, prednisone, and thalidomide versus thalidomide, dexamethasone, and pegylated liposomal doxorubicin regimen in very elderly patients with multiple myeloma: a case-match studyMassimo Offidani, Pietro Leoni, Sara Bringhen, et al.
European Journal of Haematology|March 25, 2010
ThaDD plus high dose therapy and autologous stem cell transplantation does not appear superior to ThaDD plus maintenance in elderly patients with de novo multiple myelomaMassimo Offidani, Pietro Leoni, Laura Corvatta, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 18, 2012
Assessment of vulnerability measures and their effect on survival in a real-life population of multiple myeloma patients registered at Marche Region Multiple Myeloma RegistryMassimo Offidani, Laura Corvatta, Claudia Polloni, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 5, 2014
Very low rate of readmission after an early discharge outpatient model for autografting in multiple myeloma patients: an Italian multicenter retrospective studyMassimo Martino, Mauro Montanari, Felicetto Ferrara, et al.
Critical Reviews in Oncology/Hematology|July 2, 2011
Primary plasma cell leukemia in the era of new drugs: has something changed?Pellegrino Musto, Livio Pagano, Maria Teresa Petrucci, et al.
Leukemia & Lymphoma|February 23, 2011
Infectious complications in patients with multiple myeloma treated with new drug combinations containing thalidomideMassimo Offidani, Laura Corvatta, Claudia Polloni, et al.
Haematologica|May 10, 2007
Pegylated liposomal doxorubicin in the treatment of primary cutaneous T-cell lymphomasStefano Pulini, Serena Rupoli, Gaia Goteri, et al.
American Journal of Hematology|December 23, 2016
Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trialsMassimo Gentile, Valeria Magarotto, Massimo Offidani, et al.
Pageof 15